Browse > Article
http://dx.doi.org/10.22156/CS4SMB.2021.11.11.248

Effect of Celecoxib on Lung Injury Improvement by Controlling Epithelial-Mesenchymal Transition(EMT) in Chronic Obstructive Pulmonary Disease(COPD)  

Lee, Sun-Kyung (Dept. of Biomedical Laboratory Science, Donggang University)
Publication Information
Journal of Convergence for Information Technology / v.11, no.11, 2021 , pp. 248-255 More about this Journal
Abstract
This study confirmed the effects of improving lung damage of celecoxib using an animal model of chronic obstructive pulmonary disease(COPD). It was induced in models LPS + CSE and performed in vitro and in vivo. MTT assay and real-time PCR were performed in MRC5 cells as in vitro, and mRNA expression, BALF, collagen content, and protein expression were confirmed as in vivo. Celecoxib reduced the number of inflammatory cells, cytokine and soluble protein accumulation in BALF, decreased body weight and lung weight in animal models, and improved lung collagen deposition. In addition, the reduction of EMT markers was confirmed through Western blotting and real-time PCR. Consequently, celecoxib is thought to improve lung damage of COPD induced to LPS+CSE by regulating EMT.
Keywords
COPD; EMT; Celecoxib; NSAID; Inflammation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 R. Chatterjee & J. Chatterjee. (2020). ROS and oncogenesis with special reference to EMT and stemness. Eur J Cell Biol, 99, 151073.   DOI
2 J. X. Jiang et al. (2017). Rac1 signaling regulates cigarette smoke-induced inflammation in the lung via the Erk1/2 MAPK and STAT3 pathways. Biochim Biophys Acta, 1863(7), 1778-1788. DOI : 10.1016/j.bbadis.2017.04.013   DOI
3 T. H. Chu. (2014). Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. Oncotarget, 5, 1475-1490.   DOI
4 K. H. Yoo, Y. S. Kim & S. S. Sheen. (2011). Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology, 16(4), 659-665.   DOI
5 J. C. Hogg, F Chu & S Utokaparch. (2004). The nature of small-airway obstruction in chronic obstructive pulmonary disease. New England Journal of Medicine, 350(26), 2645-2653.   DOI
6 P. J. Barnes. (2009). The cytokine network in chronic obstructive pulmonary disease. American Journal of Respiratory Cell and Molecular Biology, 41(6), 631-638.   DOI
7 P. J. Barnes. (2008). Immunology of asthma and chronic obstructive pulmonary disease. Nature Reviews Immunology, 8(3), 183-192.   DOI
8 G. G. Brusselle, G. F. Joos & K. R. Bracke. (2011). New insights into the immunology of chronic obstructive pulmonary disease. The Lancet, 378(9795), 1015-1026.   DOI
9 P Venkatesan. (2011). The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer. Biomaterials, 32, 3794-3806.   DOI
10 M. Rincon & C. G. Irvin. (2012). Role of IL-6 in asthma and other inflammatory pulmonary diseases. International Journal of Biological Sciences, 8(9), 1281-1290.   DOI
11 D. Bartis, N. Mise, R. Y. Mahida, O. Eickelberg & D. R. Thickett. (2014). Epithelial- mesenchymal transition in lung development and disease: does it exist and is it important? Thorax, 69, 760-65.   DOI
12 A. Soltani, S. Sohal. S. Weston, R. Wood-Baker & E. H. Walters. (2012). Vessel-associated transforming growth factor-beta1 (TGF-β1) is increased in the bronchial reticular basement membrane in COPD and normal smokers. PLoS ONE, 7(6), e39736.   DOI
13 M. Rincon & C. G. Irvin. (2012). Role of IL-6 in asthma and other inflammatory pulmonary diseases. International Journal of Biological Sciences, 8(9), 1281-1290.   DOI
14 N. Kaosia, S. Sukhwinder Singh, P Gregory, P Rahul & H. W. Eugene. (2014). Epithelial-mesenchymal transition as a fundamental underlying pathogenic process in COPD airways: fibrosis, remodeling and cancer. Expert Rev Respir Med, 8(5), 547-559.   DOI
15 Q. Wang, Y. Wang, Y. Zhang, Y. Zhang & W. Xiao. (2013). The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir. Res, 14, 67.   DOI
16 A. Butler, G. M. Walton & E. Sapey. (2018). Neutrophilic inflammation in the pathogenesis of chronic obstructive pulmonary disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 15(4), 392-404.   DOI
17 M. Javier, N. Rafael, J. Gustavo, P. Teresa, S. Adela & R. Mercedes. (2012). Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition. Thorax, 67(2), 147-156.   DOI
18 D. Chakroborty. (2011). Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc. Natl. Acad. Sci. USA, 108, 20730-20735.   DOI
19 V. M. Keatings, P. D. Collins, D. M. Scott & P. J. Barnes. (1996). Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. American Journal of Respiratory and Critical Care Medicine, 153(2), 530-534.   DOI
20 J. C. Hogg & W. Timens. (2009). The pathology of chronic obstructive pulmonary disease. Annual Review of Pathology: Mechanisms of Disease, 4(1), 435-459.   DOI
21 I. Tsiligianni, E. Metting, T. van der Molen, N. Chavannes & J. Kocks. (2016). Morning and night symptoms in primary care COPD patients: a cross-sectional and longitudinal study. An UNLOCK study from the IPCRG. NPJ Prim Care Respir Med, 26. 16040.   DOI
22 J. Milara, T. Peiro, A. Serrano & J. Cortijo. (2013). Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. Thorax, 68, 410-420.   DOI
23 D. G. Menter, R. L. Schilsky & R. N. DuBois. (2010). Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin. Cancer Res, 16, 1384-1390.   DOI
24 M. Xie, X Liu, X Cao, M Guo & X Li. (2020). Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017. Respir Res, 21(1), 49.   DOI